Brazil’s Spiraling Access Suits And The Potential Impact On Companies
Spending on medicines as a result of litigation against health authorities is soaring in Brazil. Scrip investigates the challenges firms may face in future, including greater pricing pressure, a more NICE-like health technology appraisal system and increased scrutiny over any perceived industry wrongdoing.
Projects In Sub-Saharan Africa Propelling Drug Approval Procedures
Sub-Saharan Africa has been firmly in the regulatory spotlight over the past year or so, with east and west Africa making progress on projects to speed up drug regulatory procedures through greater cooperation and information sharing at the regional level.
What's Behind The Success Of Korean Biosimilars?
Celltrion and Samsung Bioepis are moving fast to grab leading positions in the global biosimilars space, but how have these two firms got to where there are now? Scrip takes a look at what is driving their success and where they are heading next.
How J&J Scientist Koul Hopes To Reboot R&D At India’s IMTECH
Anil Koul, part of the Johnson & Johnson team that discovered and developed TB drug Sirturo, is currently on a sabbatical to head up IMTECH, an Indian R&D institute. Koul shares with Scrip the ups and downs of Sirturo's development journey and outlines what he hopes to achieve at IMTECH.
India CEO Pay: Local Firms Still Way Ahead Of Foreign Peers
CEOs of top Indian firms continue to earn more than their peers at leading multinational firms operating in the country and experts see limited prospects for a major change in pay structures at foreign firms, at least for now. Scrip brings you a snap-shot of CEO earnings at some leading Indian and foreign firms in 2016-17.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.